Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice
- 1 February 2005
- Vol. 23 (12) , 1507-1514
- https://doi.org/10.1016/j.vaccine.2004.08.050
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- MVA as a vector for vaccines against HIV-1Expert Review of Vaccines, 2004
- Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administrationArchiv für die gesamte Virusforschung, 2003
- Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for KenyaVaccine, 2002
- Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a VaccineJournal of Virology, 2000
- Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.Journal of General Virology, 1998
- Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.Journal of General Virology, 1998
- Host Range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus: Propagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell LineVirology, 1997
- Nonreplicating vaccinia vector efficiently expresses recombinant genes.Proceedings of the National Academy of Sciences, 1992
- Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulenceJournal of General Virology, 1991
- Studies on poxvirus infections in irradiated animalsArchiv für die gesamte Virusforschung, 1980